Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.40 |
| ▸ | LOX | P28300 | 3/20 | 0.40 |
| ▸ | UTRN | P46939 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28806544 | 0.86 | HCRTR1 (0.38) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| SCHEMBL1437199 | 0.82 | RECQL (0.47) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| SCHEMBL14925194 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| SCHEMBL13164105 | 0.82 | LOXL2 (0.61) | HCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL18083206 | 0.82 | NOS3 (0.47) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| SCHEMBL30329140 | 0.82 | RECQL (0.47) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| Hydrochloric Acid SCHEMBL25210344 | 0.81 | LOXL2 (0.59) | HCRTR1HCRTR2LOXL2LOX | |
| SCHEMBL17000198 | 0.79 | LOXL2 (0.41) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| SCHEMBL31018746 | 0.79 | LOXL2 (0.45) | HCRTR1HCRTR2LOXL2LOXUTRN | |
| Hydrochloric Acid SCHEMBL30500402 | 0.78 | LOXL2 (0.44) | HCRTR1HCRTR2LOXL2LOXUTRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2915812-A1 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | Merck Sharp & Dohme Corp. (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2473048-B1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846702-B2 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846702-B2 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011025851-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, OPRL1 | HCRTR1 199/4885HCRTR2 237/4885LOXL2 4622/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885LOXL2 1042/4885 |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, CHRM2 | HCRTR1 177/4885HCRTR2 192/4885LOXL2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.